NextCure, Inc. (NXTC)

1,6500 -0,0700 (-4,07%) Börsenschluss: 04:00PM EDT

NextCure, Inc.

9000 Virginia Manor Road
Suite 200
Beltsville, MD 20705
United States
240 399 4900
https://www.nextcure.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 82

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Michael S. Richman MSBA	Co-Founder, CEO, President & Director	698,39k	N/A	1961
Dr. Solomon Langermann Ph.D.	Chief Scientific Officer	530,32k	N/A	1960
Dr. Han Myint FACP, M.D.	Chief Medical Officer	546,66k	N/A	1954
Dr. Lieping Chen M.D., Ph.D.	Co-Founder & Chairman of Scientific Advisory Board	N/A	N/A	1957
Dr. Timothy Mayer Ph.D.	Chief Operating Officer	N/A	N/A	1965
Mr. Kevin G. Shaw	Senior VP & General Counsel	N/A	N/A	1975
Ms. Stacy Rollinger	Vice President of Human Resources	N/A	N/A	N/A
Mr. Sourav Kundu Ph.D.	Senior Vice President of Development & Manufacturing	N/A	N/A	1961
Dr. Sebastien Maloveste	Senior Vice President of Business Development	N/A	N/A	N/A
Dr. Udayan Guha M.D., Ph.D.	Senior Vice President of Clinical & Translational Development	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Corporate Governance

NextCure, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 7. Die grundlegenden Scores sind Audit: 5, Vorstand: 5, Shareholderrechte: 5, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.